Cardlytics Inc (NASDAQ:CDLX) CEO Scott D. Grimes sold 1,000 shares of the stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $30.52, for a total transaction of $30,520.00. Following the sale, the chief executive officer now owns 389,431 shares of the company’s stock, valued at approximately $11,885,434.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Scott D. Grimes also recently made the following trade(s):
- On Wednesday, January 8th, Scott D. Grimes sold 1,000 shares of Cardlytics stock. The stock was sold at an average price of $66.61, for a total transaction of $66,610.00.
NASDAQ CDLX traded up $1.36 during trading hours on Thursday, hitting $43.00. 34,290 shares of the stock were exchanged, compared to its average volume of 1,414,936. The company has a market cap of $901.92 million, a price-to-earnings ratio of -55.06 and a beta of 1.64. Cardlytics Inc has a 12-month low of $14.14 and a 12-month high of $107.50. The stock has a 50-day moving average of $70.10 and a 200 day moving average of $57.93.
Several brokerages have recently weighed in on CDLX. JPMorgan Chase & Co. decreased their target price on shares of Cardlytics from $65.00 to $47.00 and set a “neutral” rating for the company in a research note on Wednesday, March 18th. Bank of America reiterated an “average” rating and set a $100.00 target price on shares of Cardlytics in a research note on Tuesday, January 14th. BidaskClub downgraded shares of Cardlytics from a “buy” rating to a “hold” rating in a research note on Saturday, February 29th. ValuEngine raised shares of Cardlytics from a “sell” rating to a “hold” rating in a report on Tuesday, March 3rd. Finally, Craig Hallum cut shares of Cardlytics from a “buy” rating to a “hold” rating and cut their price target for the stock from $100.00 to $70.00 in a report on Wednesday, March 4th. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $66.57.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP acquired a new position in shares of Cardlytics in the 1st quarter valued at $336,000. FMR LLC raised its stake in shares of Cardlytics by 2.3% in the 1st quarter. FMR LLC now owns 3,284,572 shares of the company’s stock valued at $54,327,000 after buying an additional 72,847 shares in the last quarter. California Public Employees Retirement System raised its stake in shares of Cardlytics by 25.4% in the 3rd quarter. California Public Employees Retirement System now owns 14,800 shares of the company’s stock valued at $496,000 after buying an additional 3,000 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Cardlytics by 20.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 20,171 shares of the company’s stock worth $675,000 after purchasing an additional 3,468 shares in the last quarter. Finally, State Street Corp increased its position in shares of Cardlytics by 5.0% during the 3rd quarter. State Street Corp now owns 246,945 shares of the company’s stock worth $8,278,000 after purchasing an additional 11,812 shares in the last quarter.
Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
Further Reading: Reverse Stock Split
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.